关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
生活·健康·餘暇活動
金融
事业
制药,生物科技
细胞毒性药物
靶向治疗药物
免疫疗法
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
home
Title + Content
主题+内容
主题
内容
探索
顺序
主题
题目
日子
30
LSK BioPharma announces preliminary review of top-line results from ANGEL study
admin
2019.06.27
29
HLB to merge with US anticancer drug company LSK BioPharma
admin
2019.06.13
28
LSK BIOPHARMA AND JIANGSU HENGRUI MEDICINE ANNOUNCE FDA CLEARANCE TO INITIATE A PHASE 3 CLINICAL TRIAL IN ADVANCED HEPATOCELLUL
admin
27
ASCO-SITC Clinical Immuno-Oncology Symposium 2019 Poster of Rivoceranib AM107 Study
admin
26
LSKB ANNOUNCES THAT THE ANGEL STUDY HAS REACHED ITS PRIMARY COMPLETION DATE
admin
25
LSK BIOPHARMA TO ATTEND AND PRESENT AT THE ASCO 2017 ANNUAL MEETING
admin
24
THE US FDA GRANTS APATINIB ORPHAN DRUG DESIGNATION FOR TREATMENT OF GASTRIC CANCER
admin
23
LSK BIOPHARMA ANNOUNCES STARTING OF SITE INITIATION VISITS IN THE U.S. FOR ITS PHASE 3 GASTRIC CANCER TRIAL STUDYING APATINIB
admin
22
REGULATORY AFFAIRS ASSOCIATE November 9, 2018News JOB DESCRIPTION Responsible for compliance with applicable procedures. This
admin
21
LSKB TO REPORT NON-CLINICAL RIVOCERANIB (APATINIB) COMBINATION WITH IMMUNOTHERAPY
admin
<<
<
11
12
13
14
15